TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05655897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GeminiOne Transcatheter Valve Edge-to-Edge Repair System
Description: The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
Study: NCT05250323

Intervention type: OTHER
Intervention: observational tests in face-to-face visit
Description: All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment

Intervention type: OTHER
Intervention: observational tests in face-to-face visit
Description: All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
Study: NCT05150886

Intervention type: DIAGNOSTIC_TEST
Intervention: rox index
Description: After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.

Intervention type: DIAGNOSTIC_TEST
Intervention: rox index
Description: After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
Study: NCT06235905

Intervention type: DRUG
Group type: OTHER
Intervention: NV-5138
Description: NV-5138 is a novel , orally bioavailable, activator of mTORC1
Study: NCT05051358

Intervention type: PROCEDURE
Intervention: Therapeutic Endoscopic Ultrasound
Description: Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
Study: NCT06171490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loz-4mg
Description: The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loz-4mg
Description: The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum-4mg
Description: The Gum-4mg reference product is a commercially available 4mg nicotine gum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum-4mg
Description: The Gum-4mg reference product is a commercially available 4mg nicotine gum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum-4mg
Description: The Gum-4mg reference product is a commercially available 4mg nicotine gum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum-4mg
Description: The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Study: NCT05440760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Oculus Quest 2 Virtual Reality Headset
Description: The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Oculus Quest 2 Virtual Reality Headset
Description: The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)
Study: NCT05791903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Care Based on Kolcaba's Comfort Theory
Description: Comfort-orientated care
Study: NCT05888571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prepectoral breast reconstruction
Description: Patients receive immediate prepectoral breast reconstruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prepectoral breast reconstruction
Description: Patients receive immediate prepectoral breast reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tiloop Mesh implantation
Description: Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
Study: NCT04996576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infrazygomatic approach sphinopalatine ganglion block
Description: A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intranasal injection approach of sphinopalatine ganglion block
Description: method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
Study: NCT05069363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-Body Photobiomodulation Therapy
Description: * All participants entering the trial will receive a course of whole-body PBM therapy~* The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~* Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~* 18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~* The LED equipment delivers red and near infrared light therapy to the participant~* Session 1 = 6 minutes~* Session 2 = 12 minutes~* Sessions 3-18 = 20 minutes~* Timescale: 3 treatments/week for 6 weeks~* The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively
Study: NCT06157697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Transfer
Description: Social transfers are defined as a cash or in-kind transfer. Based on previous social transfer programs in Brazil, we will offer gift packages for mothers at 6 months. The options include: diapers, hygiene products, child developmental toys, transport vouchers, or a combination of these.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Transfer
Description: Social transfers are defined as a cash or in-kind transfer. Based on previous social transfer programs in Brazil, we will offer gift packages for mothers at 6 months. The options include: diapers, hygiene products, child developmental toys, transport vouchers, or a combination of these.
Study: NCT05271708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fespixon cream
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
Study: NCT05647382

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: blood cell analysis, blood gas surveillance, chest radiograph and echocardiography
Description: Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
Study: NCT05462548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept Injectable Product
Description: 1-1.25mg/kg every 3 weeks subcutaneous injection
Study: NCT05920486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Description: High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-Intensity Laser Therapy (HILT)
Description: Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
Study: NCT05205239

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoluminal image analysis by capsule endoscopy
Description: Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
Study: NCT05101291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
Study: NCT05652660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Probe substrate
Study: NCT06429631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile application on telephone
Description: when patient discharge from the hospital, mobile application downloaded their telephone. then researcher give feedback about patients CIC outputs.~also mobile application include 2 animations, videos, frequently asked questions and ask the expert section.
Study: NCT04770155

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Nitrates 400 mg
Description: The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Nitrates 400 mg
Description: The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline 3 g
Description: Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline 3 g
Description: Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil 100 mg
Description: Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 100 mg
Description: Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan 125 mg
Description: Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bosentan 125 mg
Description: Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
Study: NCT04859803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be received rhomboid intercostal block under ultrasound guidance.
Description: Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously \[8\]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH \& Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional intravenous analgesia
Description: Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
Study: NCT06272929

Intervention type: DEVICE
Intervention: doppler ultrasound
Description: doppler US

Intervention type: DEVICE
Intervention: doppler ultrasound
Description: doppler US
Study: NCT06450340

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.
Description: Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.
Description: Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
Study: NCT04973293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab 200 mg, 4 cycles of treatment before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
Study: NCT04924452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser conditioning and Sealant application
Description: Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 µm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm2; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sealant application
Description: Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
Study: NCT05504330

Intervention type: DRUG
Intervention: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
Study: NCT05533554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students
Description: Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre and post a month later) and 2 intervention sessions with a duration of 120 minutes each.
Study: NCT06450028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine
Description: Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine
Description: Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine
Description: Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine
Description: Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.
Study: NCT04924452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser therapy
Description: Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional rotary instruments will be used for caries removal - high-speed and low-speed dental handpieces. Restoration with compomer.